Text Size

Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Allergopharma GmbH & Co. KG
ClinicalTrials.gov Identifier:
NCT00263640
First received: December 8, 2005
Last updated: March 8, 2013
Last verified: March 2013
History of Changes
  Purpose

The trial is performed to assess efficacy and safety of the Allergopharma house dust mite allergoid in bronchial asthma.


Condition Intervention Phase
Respiratory Hypersensitivity
 Biological: Aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation
Drug: Placebo
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicentre Randomised Placebo-controlled Double-blind Clinical Trial for Evaluation of Safety and Efficacy of Specific Immunotherapy With an Alum.-Adsorbed Allergoid Preparation of House Dust Mite (D. Pteronyssinus) in Patients With Allergic Bronchial Asthma, Rhinitis, Rhinoconjunctivitis

Resource links provided by NLM:

MedlinePlus related topics: Allergy Asthma
U.S. FDA Resources

Further study details as provided by Allergopharma GmbH & Co. KG:

Primary Outcome Measures:
  • Inhalative dose of fluticasone propionate [ Time Frame: After 2 years ] [ Designated as safety issue: No ]
    The primary endpoint variate was the change of inhalative dose of fluticasone propionate needed to ensure asthma control according to GINA recommendation.


Secondary Outcome Measures:
  • Pre-bronchodilator morning peak flow [ Time Frame: After 2 years ] [ Designated as safety issue: No ]
    Post treatment, the changes from baseline in the mean pre-bronchodilator morning peak flow during the last two weeks of the diary phases were determined.


Enrollment: 130
Study Start Date: May 2005
Study Completion Date: August 2012
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo was given the same way as a subcutaneous (just under the skin) injection. Children received lifestyle counselling.
 Drug: Placebo
Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
Active Comparator: ACAROID
The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
 Biological: Aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation
The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
Other Name: ACAROID

  Eligibility

Ages Eligible for Study:   6 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Bronchial asthma
  • Requirements for inhaled corticosteroid
  • Positive skin prick test to house dust mite
  • Positive radioallergosorbent test (RAST) to house dust mite
  • Positive provocation test result to house dust mite

Exclusion Criteria:

  • Serious chronic diseases
  • Other perennial allergies
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00263640

Locations
Germany
Allergopharma GmbH & Co. KG
Reinbek, Germany, 21465
Sponsors and Collaborators
Allergopharma GmbH & Co. KG
Investigators
Principal Investigator: Annemie Narkus, M.D. Allergopharma GmbH & Co. KG
  More Information

Additional Information:
Leader in specific allergy research and therapy  This link exits the ClinicalTrials.gov site

No publications provided by Allergopharma GmbH & Co. KG

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Allergopharma GmbH & Co. KG
ClinicalTrials.gov Identifier: NCT00263640     History of Changes
Other Study ID Numbers: Al0104av, 2004-003892-35
Study First Received: December 8, 2005
Last Updated: March 8, 2013
Health Authority: Germany: Paul-Ehrlich-Institut

Keywords provided by Allergopharma GmbH & Co. KG:
House dust mite
Bronchial Asthma
Allergy
House Dust Mite Allergy

Additional relevant MeSH terms:
Asthma
Hypersensitivity
Respiratory Hypersensitivity
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Hypersensitivity, Immediate
 Immune System Diseases
Aluminum Hydroxide
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antacids
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 22, 2013